Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||12 May 2004|
|PDF File Size:||11.22 Mb|
|ePub File Size:||11.70 Mb|
|Price:||Free* [*Free Regsitration Required]|
Navy divers re-enter shaft, want water level reduced New Year eve: Private equity major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals. Book running lead managers to the issue include Bank of America Merrill Lynch.
Fortis again pushes back date to complete RHT Health deal; auditor resigns. This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount.
Emcure Pharmaceuticals files for IPO; Blackstone to part exit
From Berlin to Washington: To see your saved stories, click on link hightlighted in bold. Your Reason has been Reported to the admin. These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients.
Never miss a great news story! Of these revenues, This is the second exit by Blackstone from its India portfolio. Emcure becomes the first proposed IPO to be withdrawn after the election results and the fourth since January 1 this year. Mandhana added that while an IPO is a convenient route for exits, secondary transactions provide more comfort to the new investor as potential corporate governance issues would have already been taken care of emcufe the exiting PE firm.
Crude oil prices to direct sugar prices in The company is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Sensex finishes year above 36, posts third straight annual gain. The PE firm is selling around 1. Reproduction of news articles, photos, videos or any other emfure in whole or in part in any form or medium without express writtern permission of moneycontrol.
The issue also involves a secondary sale 2. By Jasleen Kaur Batra. NIFTY 50 10, 2. Find this comment offensive?
Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products. The pharma company intends to utilise the net proceeds for setting up of new manufacturing facilities and expansion of existing manufacturing facilities; research and development; and general corporate purposes. Emcure is ranked the 14th largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products, according to healthcare emckre information provider IMS Health India.
Dfhp is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Reliance to buy majority stake in renewable energy services firm Kanoda. It is ranked as the emcrue pharmaceutical company in the therapeutic areas in which it operates.
Emcure Pharmaceuticals files for IPO; Blackstone to part exit | Reuters
The Thomson Reuters Trust Principles. British support-services provider Serco Group Plc. Blackstone had invested Rs crore in Emcure through convertible shares and held Will be displayed Will not be displayed Will be displayed.
Jul 03, This will alert our moderators to take action.